"gp100 Melanoma Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
| Descriptor ID |
D058951
|
| MeSH Number(s) |
D12.776.543.306 D12.776.624.301.500 D23.050.285.439.500
|
| Concept/Terms |
gp100 Melanoma Antigen- gp100 Melanoma Antigen
- Antigen, gp100 Melanoma
- Melanoma Antigen, gp100
- gp100 Melanoma-Associated Antigen
- Antigen, gp100 Melanoma-Associated
- Melanoma-Associated Antigen, gp100
- gp100 Melanoma Associated Antigen
- ME20 Antigen
- Melanocyte Lineage-Specific Antigen gp100
- Melanocyte Lineage Specific Antigen gp100
- Melanocyte Protein Pmel 17
- Silver Locus Protein Homolog
- Melanoma-Associated Antigen gp100
- Melanoma Associated Antigen gp100
- Melanoma-Associated ME20 Antigen
- Antigen, Melanoma-Associated ME20
- ME20 Antigen, Melanoma-Associated
- Melanoma Associated ME20 Antigen
- MLSA gp100
- Pmel17 Melanoma Antigen
- Melanoma Antigen, Pmel17
- gp100 Melanocyte Differentiation Antigen
- Melanoma Antigen Glycoprotein 100
|
Below are MeSH descriptors whose meaning is more general than "gp100 Melanoma Antigen".
Below are MeSH descriptors whose meaning is more specific than "gp100 Melanoma Antigen".
This graph shows the total number of publications written about "gp100 Melanoma Antigen" by people in this website by year, and whether "gp100 Melanoma Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "gp100 Melanoma Antigen" by people in Profiles.
-
Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours. Cancer Treat Rev. 2019 Jul; 77:35-43.
-
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. J Biol Chem. 2019 06 07; 294(23):9198-9212.
-
Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells. Pigment Cell Melanoma Res. 2019 01; 32(1):68-78.
-
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. 2009 Feb 15; 182(4):2030-40.
-
T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. 2008 Jan; 31(1):1-6.
-
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. 2007 Feb; 117(2):492-501.
-
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):540-9.
-
Semi-allogeneic vaccines for patients with cancer and AIDS. J Immunother. 2002 Jul-Aug; 25(4):334-41.